This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Prince Joseph Kannankeril, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT01117454
First received: May 4, 2010
Last updated: May 17, 2017
Last verified: May 2017
Results First Received: February 22, 2017  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Participant;   Primary Purpose: Treatment
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions: Drug: Flecainide Acetate
Drug: Placebo
Drug: Beta blocker

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Flecainide Then Placebo

In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy first, then crossover to placebo plus standard therapy.

flecainide: oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Placebo Then Flecainide

In this crossover study, half of the subjects will be randomized to placebo plus standard therapy first, then crossover to flecainide plus standard therapy.

flecainide: oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml


Participant Flow:   Overall Study
    Flecainide Then Placebo   Placebo Then Flecainide
STARTED   6   8 
COMPLETED   6   7 
NOT COMPLETED   0   1 
Pregnancy                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Flecainide Then Placebo

In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy first, then crossover to placebo plus standard therapy.

flecainide: oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Placebo Then Flecainide

In this crossover study, half of the subjects will be randomized to placebo plus standard therapy first, then crossover to flecainide plus standard therapy.

flecainide: oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml

Total Total of all reporting groups

Baseline Measures
   Flecainide Then Placebo   Placebo Then Flecainide   Total 
Overall Participants Analyzed 
[Units: Participants]
 6   8   14 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      3  50.0%      7  87.5%      10  71.4% 
Between 18 and 65 years      3  50.0%      1  12.5%      4  28.6% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      2  33.3%      5  62.5%      7  50.0% 
Male      4  66.7%      3  37.5%      7  50.0% 
Region of Enrollment 
[Units: Participants]
     
United States   6   8   14 


  Outcome Measures

1.  Primary:   Number of Patients With Ventricular Ectopy or VT During Exercise Treadmill Testing   [ Time Frame: 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Prince J. Kannankeril, MD, MSCI
Organization: Vanderbilt University Medical Center
phone: 615 322-7447
e-mail: prince.kannankeril@vanderbilt.edu


Publications:

Responsible Party: Prince Joseph Kannankeril, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT01117454     History of Changes
Other Study ID Numbers: 100472
Study First Received: May 4, 2010
Results First Received: February 22, 2017
Last Updated: May 17, 2017